MARKET

IMRN

IMRN

Immuron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.850
+0.020
+0.42%
Suspension 16:00 05/26 EDT
OPEN
4.680
PREV CLOSE
4.850
HIGH
4.930
LOW
4.680
VOLUME
5.03K
TURNOVER
--
52 WEEK HIGH
28.99
52 WEEK LOW
1.920
MARKET CAP
27.50M
P/E (TTM)
-4.6007
1D
5D
1M
3M
1Y
5Y
Immuron Stock Appears To Be Modestly Undervalued
GuruFocus News · 06/10 08:00
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.
Benzinga · 05/27 11:04
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 05/13 12:07
Immuron Says Highlights Monash University Research Update On SARS-CoV-2 program
Key Points   Monash University Research Update on SARS-CoV-2 program Biomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in
Benzinga · 05/13 10:15
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief Medical Officer with preliminary focus on COVID-19 MELBOU...
GlobeNewswire · 05/13 10:00
Immuron Says IMM124E Product May Offer New Way of Preventing COVID-19 Infection
MT Newswires · 05/13 07:30
Bacillary Dysentery Drug Market 2021 By Manufacturers, Regions, Type and Application, Forecast to 2028 By Ameco Research
pune, India, Fri, 07 May 2021 03:31:48 / Comserve Inc. / -- The global Bacillary Dysentery Drug market is segmented by company, region (country), by Type,...
Comserve · 05/07 07:34
Global Bacillary Dysentery Drug Market Size, Share, Value, and Competitive Landscape 2020
Apr 29, 2021 (Heraldkeepers) -- The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size...
Heraldkeepers · 04/29 06:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMRN. Analyze the recent business situations of Immuron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMRN stock price target is 6.48 with a high estimate of 6.48 and a low estimate of 6.48.
EPS
Institutional Holdings
Institutions: 10
Institutional Holdings: 234.91K
% Owned: 4.14%
Shares Outstanding: 5.67M
TypeInstitutionsShares
Increased
1
2.33K
New
2
42.17K
Decreased
1
1.94K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.39%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
Roger Aston
Chief Executive Officer/Chief Operating Officer/Chief Scientific Officer
Jerry Kanellos
Vice Chairman/Director
Peter Anastasiou
Secretary
Phillip Hains
Secretary
Peter Vaughan
Director
Richard Berman
Director
Ravi Savarirayan
Non-Executive Director
Stephen Anastasiou
Non-Executive Director
Daniel Pollock
No Data
  • All
  • Financials
  • Insiders
No Data
About IMRN
Immuron Limited is a biopharmaceutical company. The Company focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The Company has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The Company sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. It also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The Company also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.

Webull offers kinds of Immuron Ltd stock information, including NASDAQ:IMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRN stock methods without spending real money on the virtual paper trading platform.